A mix-up of ingredients of Johnson & Johnson’s ( J&J ) COVID-19 vaccine and Astra Zeneca’s at an Emergent BioSolutions (EBS) manufacturing plant in Maryland ruined 15 million doses of J&Js vaccine, leading to deliveries getting halted.
The mix-up occurred about two weeks ago, and all shipments from the plant have been halted by the Food and Drug Administration. The latter in probing into the matter.
Last July, Emergent BioSolutions signed a contract, for a deal worth $480 million over the first two years, to make vaccine components for J&J .
While currently distributed J&J vaccines are not affected, the plant is supposed to produce millions of the single-shot vaccines which are expected to help the U.S. scale up its COVID-19 vaccinations in coming weeks.
EBS has manufacturing deals with several other pharmaceutical companies for vaccines including Novavax , Vaxart Inc., and Humanigen.
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where EBS declined for three days, in of 306 cases, the price declined further within the following month. The odds of a continued downward trend are .
The Momentum Indicator moved below the 0 level on September 11, 2023. You may want to consider selling the stock, shorting the stock, or exploring put options on EBS as a result. In of 83 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Aroon Indicator for EBS entered a downward trend on October 03, 2023. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 16 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Moving Average Convergence Divergence (MACD) for EBS just turned positive on September 28, 2023. Looking at past instances where EBS's MACD turned positive, the stock continued to rise in of 43 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where EBS advanced for three days, in of 280 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.171) is normal, around the industry mean (86.487). P/E Ratio (17.730) is within average values for comparable stocks, (58.641). EBS's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (3.372). EBS has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.027). P/S Ratio (0.148) is also within normal values, averaging (62.270).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. EBS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EBS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a manufacturer of biopharmaceutical products
|MFs / NAME||Price $||Chg $||Chg %|
|BBH Select Series - Large Cap Retail|
|Cromwell Greenspring Mid Cap Instl|
|Goldman Sachs Large Cap Core A|
|American Beacon Small Cp Val Inv|
|Rydex Banking Inv|
A.I.dvisor indicates that over the last year, EBS has been loosely correlated with ELAN. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if EBS jumps, then ELAN could also see price increases.